Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease
From May 1st 2022 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney disease (CKD) is fully reimbursed...
Extension to TerugBetaalRegeling Elvanse®
The health insurer does not fully reimburse Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The manufacturer of this...
Reimbursement Scheme Ontozry® (12.5mg/25mg, 50 mg, 100 mg, 150mg)
The health insurer does not fully reimburse ONTOZRY® (12.5mg/25mg, 50 mg, 100 mg, 150mg). The producer of this medicine has...
Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)
The health insurer does not yet fully reimburse Jardiance (Empagliflozin)® 10 mg for the treatment of HFpEF (Ejection fraction...
Extension to TerugBetaalRegeling Acecort®
Recently also Acecort® 2 and 3 mg tablets have been registered. The health insurer will not reimburse the cost in full. The...
Select your medicine
Check your medicine expenses
Quickly check the maximum contribution you have to pay for your medicine